Opendata, web and dolomites

TREAT-NPM1-AML SIGNED

Improving therapy of NPM1-mutated AML

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TREAT-NPM1-AML project word cloud

Explore the words cloud of the TREAT-NPM1-AML project. It provides you a very rough idea of what is the project "TREAT-NPM1-AML" about.

stratification    agents    adults    portion    previously    residual    patients    similarly    accounting    disease    flt3    clinic    stem    demonstration    seminal    vaccination    hematopoietic    transplantation    generate    untreated    41    calls    forms    aml    classification    itd    mice    discovery    mouse    terminal    first    contributions    actinomycin    mutated    discovered    clinical    unfit    promyelocytic    anti    cooperate    age    allogeneic    mutations    interacting    conventional    eudract    neoplasms    vitro    action    translation    003490    trial    drug    frequently    approximately    dnmt3a    conduct    murine    acute    18    protein    urgent    therapy    monitoring    mechanisms    15    therapeutic    strategies    interfering    gave    alone    pg02    cell    compound    functions    npm1    tools    fundamental    relapsed    older    2014    leukemia    models    lesion    genetic    minimal    molecular    cured    chemotherapy    situ    feasibility    nucleophosmin    model    leukemic    myeloid    10    understand    chemical    therapies    risk    usually    medical    50    year    combination   

Project "TREAT-NPM1-AML" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI PERUGIA 

Organization address
address: PIAZZA DELL UNIVERSITA 1
city: PERUGIA
postcode: 6123
website: www.unipg.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 2˙895˙836 €
 EC max contribution 2˙895˙836 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-ADG
 Funding Scheme ERC-ADG
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2022-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI PERUGIA IT (PERUGIA) coordinator 2˙895˙836.00

Map

 Project objective

Acute myeloid leukemia (AML) is the most common acute leukemia in adults accounting for approximately 15,000 new cases/year in Europe and 20,000 new cases/year in US. Currently, 40-50% of AML patients (age 18-60 years) and only 5-10% of older patients (who are usually more frequently affected by the disease) can be cured using conventional chemotherapy /- allogeneic hematopoietic stem cell transplantation. Thus, AML still remains an urgent medical need which calls for new forms of molecular targeted therapies (similarly to those available for acute promyelocytic leukemia). The P.I. previously discovered the nucleophosmin (NPM1) mutations, the most common genetic lesion in AML (about one-third of cases) and gave fundamental contributions in the translation of this seminal discovery into the clinic (improved classification of myeloid neoplasms according to WHO, genetic-based risk- stratification of AML patients, monitoring of minimal residual disease and first demonstration of the anti-leukemic activity of actinomycin D). The present research proposal is focused on improving therapy of NPM1-mutated AML. Specifically, it is aimed to: i) identify novel chemical tools interfering with NPM1 functions by interacting with the N-terminal portion of the protein (objective 1); ii) conduct a clinical trial (AML-PG02; Eudract 2014-003490-41) with actinomycin D in older untreated and/or unfit patients with NPM1-mutated AML and to better understand in vitro and in mice models the mechanisms of action of this drug, used alone or in combination with other agents (objective 2); iii) develop compound mouse models aimed to investigate how NPM1 mutations cooperate with FLT3-ITD or DNMT3A mutations in promoting AML with the goal to better understand the characteristics of relapsed cases and to design new therapeutic strategies (objectives 3 and 4): and iv) generate a murine model for testing the feasibility of “in situ” vaccination in AML, especially in NPM1-mutated AML (objective 5).

 Publications

year authors and title journal last update
List of publications.
2019 Paolo Sportoletti, Letizia Celani, Emanuela Varasano, Roberta Rossi, Daniele Sorcini, Chiara Rompietti, Francesca Strozzini, Beatrice Del Papa, Valerio Guarente, Giulio Spinozzi, Debora Cecchini, Oxana Bereshchenko, Torsten Haferlach, Maria Paola Martelli, Franca Falzetti, Brunangelo Falini
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations
published pages: , ISSN: 0887-6924, DOI: 10.1038/s41375-019-0399-7
Leukemia 2019-11-27
2019 Brunangelo Falini, Orietta Spinelli, Manja Meggendorfer, Maria Paola Martelli, Barbara Bigerna, Stefano Ascani, Harald Stein, Alessandro Rambaldi, Torsten Haferlach
IDH1-R132 changes vary according to NPM1 and other mutations status in AML
published pages: 1043-1047, ISSN: 0887-6924, DOI: 10.1038/s41375-018-0299-2
Leukemia 33/4 2019-11-27
2018 Lorenzo Brunetti, Michael C. Gundry, Daniele Sorcini, Anna G. Guzman, Yung-Hsin Huang, Raghav Ramabadran, Ilaria Gionfriddo, Federica Mezzasoma, Francesca Milano, Behnam Nabet, Dennis L. Buckley, Steven M. Kornblau, Charles Y. Lin, Paolo Sportoletti, Maria Paola Martelli, Brunangelo Falini, Margaret A. Goodell
Mutant NPM1 Maintains the Leukemic State through HOX Expression
published pages: 499-512.e9, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2018.08.005
Cancer Cell 34/3 2019-11-27
2018 Enrico Tiacci, Alessandra Venanzi, Stefano Ascani, Andrea Marra, Valeria Cardinali, Giovanni Martino, Veronica Codoni, Gianluca Schiavoni, Maria Paola Martelli, Brunangelo Falini
High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1 -Mutated AML
published pages: 981-984, ISSN: 0028-4793, DOI: 10.1056/nejmc1806413
New England Journal of Medicine 379/10 2019-11-27
2018 Xiaorong Gu, Quteba Ebrahem, Reda Z. Mahfouz, Metis Hasipek, Francis Enane, Tomas Radivoyevitch, Nicolas Rapin, Bartlomiej Przychodzen, Zhenbo Hu, Ramesh Balusu, Claudiu V. Cotta, David Wald, Christian Argueta, Yosef Landesman, Maria Paola Martelli, Brunangelo Falini, Hetty Carraway, Bo T. Porse, Jaroslaw Maciejewski, Babal K. Jha, Yogen Saunthararajah
Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates
published pages: 4260-4279, ISSN: 0021-9738, DOI: 10.1172/jci97117
Journal of Clinical Investigation 128/10 2019-11-27

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TREAT-NPM1-AML" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TREAT-NPM1-AML" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

EVOCELFATE (2019)

Evolution of cell fate specification modes in spiral cleavage

Read More  

ENTRAPMENT (2019)

Septins: from bacterial entrapment to cellular immunity

Read More  

CellularLogistics (2019)

Cellular Logistics: Form, Formation and Function of the Neuronal Microtubule Cytoskeleton

Read More